New drug combo targets tough breast cancer in Real-World study
Disease control
Not yet recruiting
This study looks at how well the drug inavolisib works in everyday medical practice for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a PIK3CA gene mutation. About 100 participants will receive inavolisib combined with hormone therapy,…
Sponsor: xuliang • Aim: Disease control
Last updated May 13, 2026 16:03 UTC